Journal
NEOPLASIA
Volume 13, Issue 3, Pages 276-U123Publisher
ELSEVIER SCIENCE INC
DOI: 10.1593/neo.101540
Keywords
-
Categories
Funding
- Center for Molecular Medicine Cologne [CMMC-TV46]
- EU [LSHC-CT-2004-503569, LSHB-CT-2005-512146, LSHB-CT-2006]
Ask authors/readers for more resources
Bone morphogenetic protein 7 (BMP-7) belongs to the superfamily of transforming growth factor beta-like cytokines, which can act either as tumor suppressors or as tumor promoters depending on cell type and differentiation. Our investigations focused on analyzing the effects of BMP-7 during glioma cell proliferation in vitro and in vivo. BMP-7 treatment decreased the proliferation of Gli36 Delta EGFR-LITG glioma cells up to 50% through a cell cycle arrest in the G(1) phase but not by induction of apoptosis. This effect was mediated by the modulation of the expression and phosphorylation of cyclin-dependent kinase 2, cyclin-dependent kinase inhibitor p21, and downstream retinoblastoma protein. Furthermore, in vivo optical imaging of luciferase activity of Gli36 Delta EGFR-LITG cells implanted intracranially into nude mice in the presence or absence of BMP-7 treatment corroborated the antiproliferative effects of this cytokine. This report clearly underlines the tumor-suppressive role of BMP-7 in glioma-derived cells. Taken together, our results indicate that manipulating the BMP/transforming growth factor beta signaling cascade may serve as a new strategy for imaging-guided molecular-targeted therapy of malignant gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available